CNRIP1 (Cannabinoid Receptor Interacting Protein 1) antibody is a specialized tool for detecting and studying CNRIP1, a protein that modulates cannabinoid receptor 1 (CB1R) signaling. CNRIP1 interacts with the CB1R C-terminal domain, influencing receptor trafficking, G-protein coupling, and downstream signaling pathways. This antibody is widely used in research to investigate CNRIP1's roles in synaptic plasticity, neuroprotection, and endocannabinoid system regulation.
Key Technical Details
Parameter
Details
Host Species
Rabbit (polyclonal)
Reactivity
Human, Mouse, Rat
Applications
Western Blot (WB), ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC)
Molecular Weight
Predicted: 18 kDa; Observed: 16–19 kDa
Immunogen
Synthetic peptide within human CNRIP1 (amino acids 50–100)
Storage
PBS with 0.02% sodium azide; store at -20°C
Functional Insights
Isoform-Specific Roles: CNRIP1a (164 amino acids) modulates CB1R constitutive activity, while CNRIP1b (128 amino acids) lacks this function.
Cross-Species Conservation: CNRIP1 is conserved across vertebrates, including zebrafish and rodents, but absent in invertebrates lacking CB1R.
Modulation of CB1R Signaling
Effect of CRIP1a Modulation
Mechanism
Source
Overexpression
Reduces CB1R surface levels and constitutive activity; attenuates agonist-induced internalization.
Knockdown
Increases CB1R surface expression and enhances agonist-dependent ERK phosphorylation.
G-Protein Selectivity
Suppresses Gi3/o activation while promoting Gi1/2 coupling to CB1R.
β-Arrestin Competition
Competes with β-arrestin for CB1R binding, reducing receptor internalization and β-arrestin recruitment.
Key Experimental Evidence
Agonist-Selective Effects:
CRIP1a suppresses CP55940-mediated CB1R activity but not WIN55212-2 responses.
Na⁺ concentration alters CRIP1a's ability to inhibit agonist/inverse agonist effects.
Receptor Trafficking:
CRIP1a delays CB1R recovery to the plasma membrane after prolonged agonist exposure.
Dynamin-dependent internalization of CB1R is inhibited by CRIP1a overexpression.
Biological and Clinical Relevance
Neurological Roles: CNRIP1 is highly expressed in glutamatergic and GABAergic neurons in the hippocampus, influencing synaptic transmission and plasticity.
Therapeutic Potential: CNRIP1 is studied as a drug target for pain management, neurodegenerative diseases, and psychiatric disorders due to its regulatory role in CB1R signaling.
Cancer Biomarker: Hypermethylation of the CNRIP1 promoter is linked to colorectal cancer, suggesting diagnostic utility.
Challenges and Future Directions
Isoform-Specific Tools: Current antibodies target both CNRIP1a and CNRIP1b; isoform-specific reagents are needed.
In Vivo Models: Zebrafish and rodent Cnrip1 mutants show no overt developmental defects, suggesting compensatory mechanisms or context-dependent roles.
Product Specs
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. Store at -20°C. Avoid freeze/thaw cycles.
Lead Time
Typically, we can ship products within 1-3 business days after receiving your order. Delivery times may vary depending on the purchase method or location. Please consult your local distributors for specific delivery times.
This antibody suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. It does not suppress cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels.
Gene References Into Functions
Arg82 and Cys126 of CRIP1b play a significant role in hydrogen bond interactions with the CB1 receptor and may be crucial for interactions between the CB1 receptor and CRIP1b. PMID: 28918320
CNRIP1 and RUNX3 are potential DNA methylation biomarkers for CRC diagnosis and treatment. PMID: 28940471
CRIP1a can compete with beta-arrestins for interaction with C-terminal CB1R domains, potentially affecting agonist-driven, beta-arrestin-mediated internalization of the CB1R. PMID: 27895162